ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal–Anal Task Forces whitepaperArvind Dasari, Scott Kopetz, Cathy Eng et al.|Nature Reviews Clinical Oncology|2020Cited by 365
PIK3CA mutations can initiate pancreatic tumorigenesis and are targetable with PI3K inhibitorsSusan N. Payne, Dustin A. Deming|Oncogenesis|2015Cited by 75
Abstract CT028: A first-in-human phase 1 study of LY3537982, a highly selective and potent KRAS G12C inhibitor in patients with KRAS G12C-mutant advanced solid tumorsYonina R. Murciano‐Goroff, Joshua K. Sabari, Rebecca S. Heist et al.|Cancer Research|2023Cited by 37
mTOR Inhibition Elicits a Dramatic Response in PI3K-Dependent Colon CancersDustin A. Deming, Richard B. Halberg|PLoS ONE|2013Cited by 22
Colon Cancer Tumorigenesis Initiated by the H1047R Mutant PI3KAlexander E. Yueh, Dustin A. Deming|PLoS ONE|2016Cited by 22